HBM9161 Injection (680mg)

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
11	重症筋無力症	2

11. 重症筋無力症

臨床試験数 : 332 / 薬物数 : 234 - (DrugBank : 81) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 127

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05332210 (ClinicalTrials.gov)	June 30, 2022	6/4/2022	Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myastheni ...	A Long-term Open-label Extension Study to Evaluate the Safety of HBM9161 (HL161) Subcutaneous Inject ...	Myasthenia Gravis	Drug: HBM9161 Injection (680mg)	Harbour BioMed (Guangzhou) Co. Ltd.	NULL	Recruiting	18 Years	N/A	All	144	Phase 3	China
2	NCT05039190 (ClinicalTrials.gov)	September 25, 2021	29/8/2021	Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalize ...	A Multicenter, Randomized, Double-blind, Placebo-controlled, Seamless and Group Sequential Phase 2/3 ...	Myasthenia Gravis	Drug: HBM9161 Injection (680mg);Drug: Placebo	Harbour BioMed (Guangzhou) Co. Ltd.	NULL	Completed	18 Years	99 Years	All	132	Phase 3	China

First Previous1Next Last